Neuromyelitis optica
- 1 June 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 25 (3), 215-220
- https://doi.org/10.1097/wco.0b013e3283533a3f
Abstract
Purpose of review The discovery of neuromyelitis optica (NMO)-immunoglobulin (Ig)G and its target antigen aquaporin 4 (AQP4) redefined NMO, historically considered a multiple sclerosis (MS) variant, as a specific disease entity. NMO and MS have divergent responses to immunotherapy and it is important to distinguish the conditions at disease onset. In this article, we review new pathological, imaging and clinical trial data pertaining to NMO, and discuss emerging concepts of molecular immunopathogenesis in NMO that can inform the development of targeted therapies. Recent findings Recent studies illustrate the range of brain lesions associated with NMO, and the importance of diagnostic biomarkers in patients with atypical or limited presentations. Neuropathological studies showing perivascular astrocyte destruction and preserved myelin in early NMO lesions indicate a pathogenesis distinct from MS. Characterisation of NMO-IgG binding to AQP4 isoforms and the development of novel disease models have elucidated complement-mediated and cell-mediated mechanisms of astrocyte injury. Summary NMO-IgG positive NMO is not an MS variant. Further work is required to delineate the pathogenesis of NMO syndromes without antibodies to AQP4. Methodological flaws inherent to small, open label trials of current NMO therapies limit extrapolation to clinical practice. In the coming years, NMO will be treated with targeted therapies that are emerging from an enhanced understanding of the molecular immunopathogenesis of the disease.Keywords
This publication has 49 references indexed in Scilit:
- Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytesMultiple Sclerosis Journal, 2010
- Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunityMultiple Sclerosis Journal, 2010
- Immunoglobulins and complement in postmortem multiple sclerosis tissueAnnals of Neurology, 2009
- Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosisBrain, 2007
- Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 ExpressionArchives of Neurology, 2006
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelThe Journal of Experimental Medicine, 2005
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004
- A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis opticaBrain, 2002
- The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 1999